Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

590 results about "Triple bond" patented technology

A triple bond in chemistry is a chemical bond between two atoms involving six bonding electrons instead of the usual two in a covalent single bond. The most common triple bond, that between two carbon atoms, can be found in alkynes. Other functional groups containing a triple bond are cyanides and isocyanides. Some diatomic molecules, such as dinitrogen and carbon monoxide, are also triple bonded. In skeletal formula the triple bond is drawn as three parallel lines (≡) between the two connected atoms.

10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure

InactiveUS6875787B2BiocideSenses disorderOxygenProstanoic acid
The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I; wherein the dashed line indicates the presence or absence of a bond, the hatched wedge indicates the α (down) configuration, and the solid triangle indicates the β (up) configuration;B is a single, double, or triple covalent bond;n is 0-6;X is CH2, S or O;Y is any pharmaceutically acceptable salt of CO2H, or CO2R, CONR2, NHCH2CH2OH, N(CH2CH2OH)2, CH2OR, P(O)(OR)2, CONRSO2R, SONR2, or R is H, C1-6 alkyl or C2-6 alkenyl;R2 and R3 are C1-6 linear alkyl which may be the same or different, and may be bonded to each other such that they form a ring incorporating the carbon to which they are commonly attached;R4 is hydrogen, R, C(═O)R, or any group that is easily removed under physiological conditions such that R4 is effectively hydrogen;R5 is hydrogen or R;R6 isiv) hydrogen;v) a linear or branched hydrocarbon containing between 1 and 8 carbon atoms, which may contain one or more double or triple bonds, or oxygen or halogen derivatives of said hydrocarbon, wherein 1-3 carbon or hydrogen atoms may be substituted by O or a halogen; orvi) aryloxy, heteroaryloxy, C3-8 cycloalkyloxy, C3-8 cycloalkyl, C6-10 aryl or C3-10 heteroaryl, wherein one or more carbons is substituted with N, O, or S; and which may contain one or more substituents selected from the group consisting of halogen, trihalomethyl, cyano, nitro, amino, hydroxy, C6-10 aryl, C3-10 heteroaryl, aryloxy, heteroaryloxy, C1-6 alkyl, OR, SR, and SO2R.Some of the compounds of the present invention and some of their methods of preparation are also novel an nonobvious.
Owner:ALLERGAN INC

Antibacterial fabric and preparing method thereof

The invention relates to a type of antibacterial fabric and a preparing method thereof, with the preparing method comprising: adsorbing cross-linking agent to the surface of fabric containing C-H key to obtain the fabric adsorbing cross-linking agent; taking the fabric adsorbing cross-linking agent as filter cloth for filtering oxidation graphite alkene aqueous solution to obtain the fabric containing both the cross-linking agent and the oxidation graphite alkene; and employing radiation crosslinking method or heat crosslinking method to initiate the cross-linking agent upon the fabric containing both the cross-linking agent and the oxidation graphite alkene for crosslinking polymerization, thus to obtain antibacterial fabric, wherein the cross-linking agent contains more than two carbon-carbon double bonds and/or Carbon-carbon triple bonds. The method of the invention is easy to operate, consumes less amount of oxidation graphite alkene, uses less amount of time in post-treatment period, and is of low cost and suitable for large scale industrialized production. Moreover, the antibacterial fabric made in this way keeps great antibacterial performance even after repeated washing. With the cytotoxicity at Level 0 (the highest security level), the antibacterial fabric produces nearly no irritation to skin.
Owner:JINAN SHENGQUAN GROUP SHARE HLDG

Aryl substituted 3,4-dihydroanthracene derivatives having retinoid antagonist or retinoid inverse agonist type biological activity

InactiveUS7166726B2Susceptibility to treatmentReduce adverse effectsSenses disorderNervous disorderArylSilylene
Disclosed herein are compounds of the formula
wherein R1 is independently H or alkyl of 1 to 6 carbons;
  • R2 is optional and is defined as lower alkyl of 1 to 6 carbons, F, Cl, Br, I, CF3, fluoro substituted alkyl of 1 to 6 carbons, OH, SH, alkoxy of 1 to 6 carbons, or alkylthio of 1 to 6 carbons;
  • n is an integer of between 0 and 2;
  • o is an integer between 0 and 3;
  • R3 is hydrogen, lower alkyl of 1 to 6 carbons, F, Cl, Br or I;
  • R4 is heteroaryl or (R5)p-heteroaryl where the heteroaryl group is 5-membered or 6-membered and has 1 to 3 heteroatoms selected from the group consisting of O, S, and N;
  • p is an integer having the values of 0–5;
  • R5 is F, Cl, Br, I, NO2, N(R8)2, N(R8)CORO8, N(R8)CON(R8)2, OH, OCOR8, OR8, CN, COOH, COOR8, C1-10 alkyl, fluoro substituted C1-10 alkyl, C2-10 alkenyl having 1 to 3 double bonds, C2-10 alkynyl having 1 to 3 triple bonds, or a (trialkyl)silyl or (trialkyl)silyloxy group where the alkyl groups independently have 1 to 6 carbons;
  • A is (CH2)q where q is 0–5, C3-6 branched alkyl, C3-6 cycloalkyl, C2-6 alkenyl having 1 or 2 double bonds, or C2-6 alkynyl having 1 or 2 triple bonds;
  • B is hydrogen, COOH or a pharmaceutically acceptable salt thereof, COORO8, CONR9R10, CH2OH, CH2OR11, CH2OCOR11, CHO, CH(OR12)2, CHOR13O, COR7, CR7(OR12)2, CR7OR13O, or Si(C1-6alkyl)3;
  • R7 is C1-5 alkyl, C3-5 cycloalkyl, or C2-5 alkenyl;
  • R8 is C1-10 alkyl, C1-10 (trimethylsilyl)alkyl, or C5-10 cycloalkyl;
  • R9 and R10 are independently hydrogen, C1-10 alkyl, C5-10 cycloalkyl, phenyl or R12-phenyl;
  • R11 is C1-6 alkyl, phenyl, or R12-phenyl;
  • R12 is C1-6 alkyl; and
  • R13 is divalent alkyl radical of 2–5 carbons.
Owner:ALLERGAN INC

10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure

The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I; wherein the dashed line indicates the presence or absence of a bond, the hatched wedge indicates the alpha (down) configuration, and the solid triangle indicates the beta (up) configuration; B is a single, double, or triple covalent bond; n is 0-6; X is CH2, S or O; Y is any pharmaceutically acceptable salt of CO2H, or CO2R, CONR2, CONHCH2CH2OH, CON(CH2CH2OH)2,CH2OR, P(O)(OR)2, CONRSO2R, SONR2, or R is H, C1-6 alkyl or C2-6 alkenyl; R<2 >and R<3 >are C1-6 linear alkyl which may be the same or different, and may be bonded to each other such that they form a ring incorporating the carbon to which they are commonly attached; R<4>is hydrogen, R, C(=O)R, or any group that is easily removed under physiological conditions such that R<4 >is effectively hydrogen; R<5 >is hydrogen or R; R<6 >is i) hydrogen; ii) a linear or branched hydrocarbon containing between 1 and 8 carbon atoms, which may contain one or more double or triple bonds, or oxygen or halogen derivatives of said hydrocarbon, wherein 1-3 carbon or hydrogen atoms may be substituted by O or a halogen; or iii) aryloxy, heteroaryloxy, C3-8 cycloalkyloxy, C3-8 cycloalkyl, C6-10 aryl or C3-10 heteroaryl, wherein one or more carbons is substituted with N, O, or S; and which may contain one or more substituents selected from the group consisting of halogen, trihalomethyl, cyano, nitro, amino, hydroxy, C6-10 aryl, C3-10 heteroaryl, aryloxy, heteroaryloxy, C1-6 alkyl, OR, SR, and SO2R. Some of the compounds of the present invention and some of their methods of preparation are also novel an nonobvious.
Owner:ALLERGAN INC

Nonaqueous electrolyte solution and lithium secondary battery using same

Disclosed is a nonaqueous electrolyte solution which is excellent in battery characteristics such as battery capacity, cycle characteristics and storage characteristics and is capable of maintaining adequate battery performance for a long time. Also disclosed is a lithium secondary battery using such a nonaqueous electrolyte solution. Specifically disclosed is a nonaqueous electrolyte solution for lithium secondary batteries wherein an electrolyte salt is dissolved in a nonaqueous solvent. This nonaqueous electrolyte solution contains 0.1-10% by weight of an ethylene carbonate derivative represented by the general formula (I) below, and 0.01-10% by weight of a triple bond-containing compound (A) and/or a pentafluorophenyloxy compound (B) represented by the general formula (X) below. Also specifically disclosed is a lithium secondary battery using such a nonaqueous electrolyte solution. [Chemical formula 1] (I) (In the formula (I), R<1>-R<3> respectively represent a hydrogen atom, a halogen atom, an alkenyl group, an alkynyl group or an aryl group. In this connection, ethylene carbonates are excluded.) [Chemical formula 2] (X) (In the formula (X), R<15> represents an alkylcarbonyl group, an alkoxycarbonyl group, an aryloxycarbonyl group or an alkanesulfonyl group.
Owner:MU IONIC SOLUTIONS CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products